ESMO China Voice | Professor Li Wenbin: Breaking the Blood-Brain Barrier — Novel Targeted and Chemotherapy Regimens Bring a Survival Breakthrough for Recurrent Glioma

ESMO China Voice | Professor Li Wenbin: Breaking the Blood-Brain Barrier — Novel Targeted and Chemotherapy Regimens Bring a Survival Breakthrough for Recurrent Glioma

Recurrent high-grade glioma (HGG) has an extremely poor prognosis, particularly in IDH-wildtype patients, with a median overall survival (OS) of only 6–10 months. Despite progress in targeted therapy, the treatment of central nervous system (CNS) tumors remains a significant challenge due to the physiological barrier of the blood-brain barrier (BBB). At the 2026 European Society for Medical Oncology (ESMO) Congress, Professor Wenbin Li’s team from the Comprehensive Neuro-Oncology Center, Beijing GoBroad Hospital, presented two research findings: a Phase I oral presentation on the novel BRAF inhibitor HSK42360 in recurrent glioma, and multicenter, large-sample prospective data on teniposide combined with platinum for recurrent HGG. On October 31, the 6th iHope Innovative Medicine Forum was held. With the construction of the ARO (Academic Research Organization) clinical research system as its core, the forum demonstrated Beijing GoBroad Hospital’s strength in building a multinational, multicenter clinical research system and translating cutting-edge technologies. Oncology Frontier invited Professor Li Wenbin to interpret the breakthroughs in clinical translation of innovative drugs and the evolving landscape of neuro-oncology treatment from the perspectives of translational medicine and clinical research.
Professor Alberto Briganti: Evaluating the Value of Perioperative Intensification Against Surgery Alone — Study Design, Pathological Findings, and Patient Selection in the PROTEUS Subgroup Analysis

Professor Alberto Briganti: Evaluating the Value of Perioperative Intensification Against Surgery Alone — Study Design, Pathological Findings, and Patient Selection in the PROTEUS Subgroup Analysis

For patients with high-risk localized or locally advanced prostate cancer who are candidates for surgery, the clinical value of perioperative treatment intensification compared with surgery alone, as well as the identification of patients most likely to benefit, remain central questions in current clinical research. At the 2026 European Society for Medical Oncology (ESMO) Congress, the PROTEUS subgroup analysis reported a direct comparison of perioperative apalutamide plus androgen deprivation therapy (ADT) followed by surgery versus surgery alone. Oncology Frontier – UroStream invited the study presenter, Professor Alberto Briganti of Vita-Salute San Raffaele University in Milan, Italy, to discuss the study design, pathological findings, and their potential relationship with long-term outcomes, as well as how further subgroup analyses and biomarker assessments may help identify patients most likely to benefit from treatment intensification.
4th One Health | Professor Patrick Harris: Clinical Trials for Multidrug-Resistant Gram-Negative Bacteria—Current Landscape, Challenges, and Future Directions

4th One Health | Professor Patrick Harris: Clinical Trials for Multidrug-Resistant Gram-Negative Bacteria—Current Landscape, Challenges, and Future Directions

Infections caused by multidrug-resistant Gram-negative bacteria have become a major threat to global public health, yet clinical research on the related antibacterial agents has long been confronted with challenges such as complex trial design, pronounced heterogeneity of resistance mechanisms, and unequal access to drugs. At the 4th One Health Conference of Antimicrobial Resistance Containment, Professor Patrick Harris of the Royal Brisbane and Women's Hospital, Australia, gave a dedicated presentation entitled "Clinical Trials in Multidrug-Resistant Gram-Negative Bacteria — Where Are We? What Do We Need?" Infectious Disease Frontier invited Professor Patrick Harris for an in-depth dialogue on the difficulties of clinical trial design, progress in novel agents, international collaboration, and infection prevention and control.
ESMO 2026 LBA | EGFR×HER3 Bispecific ADC Iza-bren Reshapes the Treatment Landscape of Advanced HR+/HER2− Breast Cancer, Becoming the First Chinese Innovative Drug in Breast Cancer to Be Published in The Lancet

ESMO 2026 LBA | EGFR×HER3 Bispecific ADC Iza-bren Reshapes the Treatment Landscape of Advanced HR+/HER2− Breast Cancer, Becoming the First Chinese Innovative Drug in Breast Cancer to Be Published in The Lancet

From October 23 to 27, 2026, the European Society for Medical Oncology (ESMO) Congress was held in Madrid, Spain. At the meeting, iza-bren (BL-B01D1), an innovative EGFR×HER3 bispecific antibody–drug conjugate (BsADC) independently developed by SystImmune, made a remarkable appearance with data from its pivotal Phase III PANKU-Breast01 study. As a first-in-class, new-concept therapeutic, the agent's prespecified interim analysis results were presented in full for the first time worldwide in a late-breaking abstract (LBA).
ESMO 2026 | Professor Wei Xu: From Tumor Shrinkage to Surgery—Exploring a New Neoadjuvant Treatment Strategy for Head and Neck Squamous Cell Carcinoma with Iparomlimab, Tovoricimab, and Chemotherapy

ESMO 2026 | Professor Wei Xu: From Tumor Shrinkage to Surgery—Exploring a New Neoadjuvant Treatment Strategy for Head and Neck Squamous Cell Carcinoma with Iparomlimab, Tovoricimab, and Chemotherapy

Neoadjuvant treatment for locally advanced head and neck squamous cell carcinoma (LA-HNSCC) must achieve tumor regression and improve the likelihood of surgery while minimizing the impact on organ function and quality of life. At the 2026 European Society for Medical Oncology (ESMO) Congress, preliminary results were reported from an exploratory study evaluating neoadjuvant iparomlimab and tovoricimab (hereafter referred to as the “combination antibody regimen”) plus nab-paclitaxel and nedaplatin. As of April 2026, 12 patients had been enrolled. The cohort included a relatively high proportion of patients with hypopharyngeal cancer, and most patients had a PD-L1 combined positive score (CPS) of less than 20. The study reported high objective response and pathological response rates. However, this was a small, single-arm exploratory study, and the findings require validation through controlled studies and long-term follow-up. Oncology Frontier interviewed Professor Wei Xu about the study design, interpretation of pathological response, appropriate patient populations, and functional outcomes.
ESMO LBA Insights | Professor Shaodong Hong Discusses TAISHAN-301: Doubling the Response Rate in Nasopharyngeal Carcinoma and Offering a New Later-Line Treatment Option

ESMO LBA Insights | Professor Shaodong Hong Discusses TAISHAN-301: Doubling the Response Rate in Nasopharyngeal Carcinoma and Offering a New Later-Line Treatment Option

Nasopharyngeal carcinoma (NPC), often referred to as the “Guangdong cancer,” is particularly prevalent in southern China. First-line treatment with gemcitabine plus platinum-based chemotherapy combined with a PD-1 inhibitor has become the standard of care. However, for patients with recurrent or metastatic (R/M) disease whose cancer progresses following immunotherapy and platinum-based chemotherapy, later-line treatment options remain limited. Treatment still relies primarily on single-agent chemotherapy, such as gemcitabine and docetaxel, with objective response rates (ORRs) of only 10%–30% and median progression-free survival (PFS) of approximately 3–4 months. An effective standard treatment for this setting has long been lacking.
ESMO 2026 | Interim Results from a Neoadjuvant Study in Locally Advanced Cervical Cancer: QL1706 Plus Chemotherapy, with 14 Patients Undergoing Surgery

ESMO 2026 | Interim Results from a Neoadjuvant Study in Locally Advanced Cervical Cancer: QL1706 Plus Chemotherapy, with 14 Patients Undergoing Surgery

Concurrent chemoradiotherapy remains the standard treatment for locally advanced cervical cancer. For high-risk patients with a substantial tumor burden, extensive local invasion, or lymph node metastases, rapidly reducing tumor burden early in treatment and creating favorable conditions for subsequent definitive therapy remain important clinical challenges.
ESMO 2026 Voices from China | Professor Li Zhang and Professor Hongyun Zhao’s Team Presents First Large-Scale Dataset on Novel EGFR/c-Met Bispecific ADC HS-20122

ESMO 2026 Voices from China | Professor Li Zhang and Professor Hongyun Zhao’s Team Presents First Large-Scale Dataset on Novel EGFR/c-Met Bispecific ADC HS-20122

For patients with EGFR-mutated non-small cell lung cancer (NSCLC), resistance following EGFR tyrosine kinase inhibitor (TKI) treatment is almost inevitable. The challenge becomes particularly pronounced when resistance develops to third-generation EGFR-TKIs, leaving patients with limited subsequent treatment options and a persistent need for improved efficacy. It is against this backdrop of unmet clinical need that a novel dual-targeted agent has entered the clinical spotlight: HS-20122, a bispecific antibody-drug conjugate (ADC) targeting both EGFR and c-Met.